PHOENIX—Miguel Regueiro, MD, the chief of the Digestive Disease Institute and a professor of medicine at Cleveland Clinic, in Ohio, sat down with Gastroenterology & Endoscopy News at ACG 2025 to discuss his favorite inflammatory bowel disease research presented at the conference.
His highlights included the ASTRO study, which examined the efficacy of subcutaneous guselkumab (Tremfya, Johnson & Johnson) induction therapy; a study that led to an expanded indication for upadacitinib (Rinvoq, AbbVie); and promising new data on TL1A inhibitors.
“It's been an incredibly engaging conference,” Dr. Regueiro said, “[with] a lot of wonderful presentations on inflammatory bowel disease.”
—GEN Staff